4//SEC Filing
THOMPSON PHILLANDAS T. 4
Accession 0001140361-17-035549
CIK 0001012477other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 5:09 PM ET
Size
11.7 KB
Accession
0001140361-17-035549
Insider Transaction Report
Form 4
THOMPSON PHILLANDAS T.
See Remarks
Transactions
- Purchase
ADSs
2017-09-13$9.36/sh+5,000$46,800→ 63,000 total
Holdings
- 100,000
Stock Option (right to buy)
Exercise: $14.35Exp: 2025-12-10→ ADSs (100,000 underlying) - 100,000
Stock Option (right to buy)
Exercise: $7.36Exp: 2023-12-12→ ADSs (100,000 underlying) - 95,000
Stock Option (right to buy)
Exercise: $16.30Exp: 2024-12-11→ ADSs (95,000 underlying) - 100,000
Stock Option (right to buy)
Exercise: $10.40Exp: 2026-12-14→ ADSs (100,000 underlying)
Footnotes (7)
- [F1]The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts..
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.34 to $9.38, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).
- [F3]Includes (a) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 20,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (c) 18,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- [F4]Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2013 grant date.
- [F5]Options become exercisable as to 23,750 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
- [F6]Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- [F7]Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Documents
Issuer
AVADEL PHARMACEUTICALS PLC
CIK 0001012477
Entity typeother
Related Parties
1- filerCIK 0001661781
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 5:09 PM ET
- Size
- 11.7 KB